SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending following FDA clearance to use its commercially manufactured GP2 lot in the Phase III FLAMINGO-01 trial, a crucial manufacturing milestone for its breast cancer immunotherapy. The community is actively discussing this as a significant de-risking event for the company's Biologics License Application, fueling speculation around a potential short squeeze due to high borrow rates and a notably tight float. Investor sentiment is further buoyed by observed consistent insider buying, reinforcing confidence in the stock's future trajectory.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SU Group Holdings Ltd (SUGP) is trending due to intense community discussion centered on its ultra-low share float and significant short interest, leading to strong speculation about a potential short squeeze. Traders are keenly drawing comparisons to past high-volatility runners within the "Hong Kong low float" theme, with sentiment further fueled by a high cost to borrow and anticipation of upcoming earnings or contract news as potential catalysts for a substantial price movement. The company's recent fiscal year financial results reporting revenue growth in security-related engineering services also contribute to the bullish sentiment among market participants.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is experiencing significant bullish momentum after the U.S. government, via NOAA, streamlined deep-sea mining permits, signaling a faster path to commercial recovery for critical minerals. This regulatory de-risking, coupled with an upcoming Congressional hearing featuring TMC's CEO, is driving community discussions around national security priorities, long-term value, and the potential for a substantial short squeeze.

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.

Janux Therapeutics Inc

Janux Therapeutics is currently trending as investors debate its valuation following updates on its JANX008 study and subsequent analyst re-ratings, which occurred after prior mixed data from its JANX007 program caused a significant price decline. The community is heavily focused on the stock trading below its cash value, fueling discussions around a potential short squeeze and persistent rumors of a Merck buyout. Despite some frustration with market action and management, many believe the stock is oversold and poised for a rebound, reflecting the volatile nature of clinical-stage biotech.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is a major talking point following news of a Neutron rocket tank rupture during qualification testing. The community is split, with many highlighting it as a standard and intentional stress test crucial for validating structural limits, akin to industry peers, while others are concerned about potential development delays. This critical step for the future Neutron rocket is unfolding amidst Rocket Lab's strong Electron launch cadence and growing defense sector presence.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending as investors anticipate its upcoming Q4 earnings report, with community sentiment sharply divided between hopes for AR/AI advancements and concerns over historical post-earnings declines. The company also faces increasing scrutiny regarding potential global social media bans for minors, which is adding significant regulatory pressure to its user growth outlook, while ongoing discussions about CEO share sales continue to fuel investor debate.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is trending due to a significant new investment from Steve Cohen's Point72, signaling strong institutional confidence in the company. This comes as the community eagerly awaits initial sales data for their recently launched fibromyalgia drug, Tonmya, and anticipates updates on its promising Lyme disease prevention pipeline. Despite some historical skepticism, many believe this institutional backing, combined with future commercial execution, positions the biotech for a notable re-evaluation.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileye is trending following its earnings report, which delivered revenue declines and cautious 2026 guidance, alongside a strategic acquisition of Mentee Robotics to expand into humanoid AI. Community sentiment is deeply divided, with many expressing frustration over the stock's continued decline despite this expansion and an earlier major US automaker deal. Investors are grappling with whether the stock is significantly undervalued or experiencing sustained selling pressure, amidst concerns about valuation and market perception.

Procter & Gamble Co. engages in the provision of branded consumer packaged goods. It operates through the following segments: Beauty, Grooming, Health Care, Fabric and Home Care, and Baby, Feminine and Family Care. The Beauty segment offers hair, skin, and personal care. The Grooming segment consists of shave care like female and male blades and razors, pre and post shave products, and appliances. The Health Care segment includes oral care products like toothbrushes, toothpaste, and personal health care such as gastrointestinal, rapid diagnostics, respiratory, and vitamins, minerals, and supplements. The Fabric and Home care segment consists of fabric enhancers, laundry additives and detergents, and air, dish, and surface care. The Baby, Feminine and Family Care segment sells baby wipes, diapers, and pants, adult incontinence, feminine care, paper towels, tissues, and toilet paper. The company was founded by William Procter and James Gamble in 1837 and is headquartered in Cincinnati, OH.

Procter & Gamble Co.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed (PAVM) is experiencing significant market attention following its subsidiary Lucid Diagnostics securing a pivotal U.S. Department of Veterans Affairs contract for its EsoGuard esophageal DNA test. This agreement, poised to expand precancer screening for millions of veterans, has ignited bullish discussions around a potential short squeeze given the stock's low float, though some community members are highlighting historical volatility and concerns about potential dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AbbVie Inc. (NYSE:ABBV) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of AbbVie Inc. (NYSE:ABBV - Get Free Report) have earned an average rating of "Moderate Buy" from the twenty-three brokerages that are currently covering the stock, MarketBeat reports. Eight...

Promising Dividend Stocks To Watch Today - January 21st

AbbVie, Exxon Mobil, Direxion Daily TSLA Bull 2X Shares, Chevron, and Xcel Energy are the five Dividend stocks to watch today, according to MarketBeat's stock screener tool. Dividend stocks are...

Promising Pharmaceutical Stocks To Add to Your Watchlist - January 21st

Eli Lilly and Company, AbbVie, and Novo Nordisk A/S are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly...

Top Medical Stocks To Follow Now - January 21st

Eli Lilly and Company, UnitedHealth Group, Johnson & Johnson, AbbVie, and Novo Nordisk A/S are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks...

208,510 Shares in AbbVie Inc. $ABBV Purchased by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. purchased a new stake in AbbVie Inc. (NYSE:ABBV - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund...

AbbVie Inc. $ABBV Shares Purchased by Migdal Insurance & Financial Holdings Ltd.

Migdal Insurance & Financial Holdings Ltd. raised its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 96.5% during the 3rd quarter, according to the company in its most recent filing with the...

Vest Financial LLC Has $72.41 Million Position in AbbVie Inc. $ABBV

Vest Financial LLC lowered its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 2.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC...

Bailard Inc. Acquires 16,049 Shares of AbbVie Inc. $ABBV

Bailard Inc. boosted its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 54.8% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 45,353...

Dividend Stocks To Follow Now - January 20th

Exxon Mobil, Chevron, Direxion Daily TSLA Bull 2X Shares, Merck & Co., Inc., Kenvue, Pfizer, and AbbVie are the seven Dividend stocks to watch today, according to MarketBeat's stock screener tool...

Triasima Portfolio Management inc. Invests $2.80 Million in AbbVie Inc. $ABBV

Triasima Portfolio Management inc. acquired a new position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The...

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Current Price	$216.15
Prev Close	$214.04
Open	$212.47
Dividend Yield	3.54%
50-Day Moving Average	$226.06
Beta	0.32
Avg. Volume	5.09M
PE Ratio	163.10

52-Week High	$244.81
52-Week Low	$164.39
Market Capitalization	$385.56B
EPS (Annual)	$2.39
Price to Book	-144.59
Revenue Per Employee	$1.02M
Enterprise Value/EBITDA	N/A

ABBV
Abbvie Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ABBV News

ABBVAbbvie Inc